New PET scan could spot hidden kidney cancer after treatment
NCT ID NCT07077083
First seen Jun 27, 2026 · Last updated Jul 22, 2026 · Updated 2 times
Summary
This study tests whether a special PET scan using a drug called 89Zr-girentuximab can detect kidney cancer that remains or comes back after initial treatment. Ten adults with clear cell renal cell carcinoma will receive the drug and then have a PET scan. Some will also have a second scan after standard cryoablation treatment to see how the scan changes. The goal is to improve detection of residual or recurrent cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CCRCC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill that starves tumors of oxygen help fight advanced cancer?
- New scan aims to spot hidden kidney cancers without surgery
- New Immune-Boosting drug combo targets Hard-to-Treat cancers
- New combo tackles kidney cancer that came back after immunotherapy
- New drug combo may help save kidneys in High-Risk cancer patients
- New drug combo aims to shrink hard-to-treat tumors